A Agilent Technologies Inc.

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025

Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph.

The updated release reads:

AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025

(NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency.

In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzing tissue samples, often for diagnosing diseases such as cancer. In collaboration with , , , and , Agilent has developed an innovative end-to-end digital pathology workflow. This solution integrates AI-driven precision pathology software with automated staining solutions, significantly improving diagnostic quality and efficiency. Agilent's workflow covers everything from scanning tissue samples to analyzing images and managing data, incorporating advanced technologies like AI to enhance accuracy and efficiency.

"Agilent's innovative pathology solutions are transforming health care by ensuring precise, timely, and reliable diagnoses. Our comprehensive digital pathology workflows and advanced staining technologies enable laboratories to deliver accurate and comprehensive results, facilitating faster and more effective treatments,” said Nina Green, vice president and general manager of the Clinical Diagnostics Division at Agilent. “By reducing the time from biopsy to diagnosis and enhancing diagnostic consistency, we help support better therapeutic decisions."

USCAP attendees are invited to live demonstrations of Agilent’s digital pathology solutions, including scanning, image management, and AI-driven image analysis. Covering primary, special, IHC, and ISH staining, Agilent’s automated, integrated, and advanced tissue staining solutions deliver consistent, high-quality results, helping laboratories enhance productivity and reduce the time from biopsy to diagnosis. Agilent will also showcase key products that play crucial roles in pathology labs including the and the .

Additionally, a Digital Pathology Symposium, “Advancing Diagnostics: Cutting-Edge Innovations and Insights in Digital Pathology,” will be held Monday, March 24, from 12:00–1:00 PM ET, featuring presenters including Dr. Douglas Clark and Jake Eden from Agilent, Dr. Orly Ardon from Memorial Sloan Kettering Cancer Center, Dr. Dominique Coco from Cellnetix Olympia, Dr. Anil Parwani from The Ohio State University, and Dr. Brian Robinson from Weill Cornell Medicine. A Medical Affairs Symposium, “PD-L1 Heterogeneity Across the Patient Journey,” will also be held Monday, March 24, from 5:30–7:00 PM ET, and presented by Dr. Matteo Fassan from the University of Padua in Italy. For more information about these events and Agilent's pathology solutions, visit the AUSCAP Agilent booth #512.

For more information about these events and Agilent's pathology solutions, visit the USCAP Agilent booth #512.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the . Follow Agilent on and .

EN
20/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch